Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 June 2025 | Story Dr Nitha Ramnath | Photo Lunga Luthuli
Dr Omololu Aluko
Dr Omololu Aluko, Senior Lecturer in the Department of Biostatistics advances health research and collaboration during prestigious fellowship at Ghent University, Belgium.

Dr Omololu Aluko, Senior Lecturer in the Department of Biostatistics in the Faculty of Health Sciences at the University of the Free State (UFS), recently completed a prestigious short research stay at Ghent University in Belgium. The fellowship, hosted in April 2025, was awarded through the highly competitive Africa Platform of Ghent University Association (GAP) funding scheme, with additional support from the UFS International Office. 

A recognised expert in infectious disease modelling, particularly HIV/AIDS research in low-resource settings, Dr Aluko has devoted his academic career to using biostatistics to address pressing health challenges. His selection for this fellowship marks a significant achievement both for his individual research trajectory and for the broader ambitions of the Faculty of Health Sciences and the UFS.

 

Strategic steps towards international collaboration 

The opportunity for the fellowship was first announced in the UFS Digest Newsletter. Motivated by the potential for international collaboration, Dr Aluko began seeking a host at Ghent University whose interests aligned with his own. After several weeks of correspondence with various departments and researchers, a suitable academic collaborator agreed to host him. 

With a host confirmed, Dr Aluko submitted his application, which underwent a rigorous review and selection process. His proposal was shortlisted and ultimately approved. While Ghent University provided partial funding, supplementary financial support was secured through the UFS International Office. Dr Aluko credits the office’s assistance – especially the guidance of Mr Kagiso Ngake, Senior Officer: Partnerships – for helping him successfully secure the necessary resources. 

 

Advancing research in health data science  

During his time at Ghent University, Dr Aluko focused on the application of machine learning algorithms to address public health challenges – an increasingly important field within the Faculty of Health Sciences. His research demonstrated how advanced data analysis techniques can improve health outcomes and optimise treatment strategies, especially in resource-constrained settings. 

Beyond the immediate research achievements, the fellowship laid a foundation for long-term collaboration between the UFS and Ghent University. Key outcomes include: 

  • Opportunities for joint PhD supervision, allowing UFS students to conduct part of their research at Ghent University 
  • Prospects for publishing collaborative research in leading international A1-rated journals 
  • The identification of a promising young research collaborator, paving the way for future academic partnerships 
  • Plans to explore future staff exchange programmes, as new funding calls are announced 

     

A growing partnership in a new academic field 

Dr Annelies Verdoolaege, Coordinator for the Africa Platform at Ghent University, emphasised the broader vision behind the initiative:

“The purpose of these fellowships is to foster structural academic collaboration between Ghent University and partners in Africa. We offer a dedicated amount of seed funding to support short-term mobility, with the aim of building long-term partnerships – through student exchange, joint PhDs, joint funding proposals, and collaborative research publications. 

The UFS is a long-standing partner of Ghent University, especially in Education, Linguistics, and Agriculture. We are delighted that this fellowship has taken place in the field of Data Analysis and Mathematical Modelling - a scientific domain still to be fully developed between our institutions.” 

 

Enhancing UFS’ global research impact 

Dr Aluko’s successful fellowship reflects the high calibre of researchers at the UFS and illustrates the importance of international academic mobility. By securing this competitive opportunity, Dr Aluko not only advanced his own work but also strengthened the UFS’ global research footprint - opening new collaborative avenues and reinforcing the university's growing reputation in health sciences and data-driven research. 

The UFS expresses its sincere gratitude to the Africa Platform of Ghent University and the UFS International Office for their critical support in enabling this milestone. Partnerships such as this are key to fulfilling the UFS’ mission of producing world-class research and fostering meaningful global engagement. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept